Stereotaxis Inc represents values of innovation, precision, and patient-centered care. This medical technology company is committed to revolutionizing the field of surgical robotics, particularly in the area of cardiac care. Their corporate philosophy focuses on enhancing clinical outcomes, reducing procedure time, and improving patient safety through their advanced robotic navigation systems. Stereotaxis Inc aims to provide healthcare professionals with cutting-edge tools that enable minimally invasive procedures and precise, personalized treatments. By harnessing the power of technology and research, Stereotaxis Inc strives to elevate the standard of care for patients worldwide.

Stereotaxis Inc is primarily present in the United States.

Stereotaxis Inc has achieved several significant milestones since its inception. Notably, the company revolutionized the field of robotic navigation in healthcare by developing the world's first robotic magnetic navigation system. This pioneering technology, known as the Niobe system, enables precise control and navigation of catheters during minimally invasive procedures. Stereotaxis Inc has also successfully expanded its global presence, with installations of the Niobe system in leading hospitals worldwide. Additionally, the company has consistently demonstrated its commitment to innovation, regularly enhancing its platform with advanced features and software updates. These accomplishments have solidified Stereotaxis Inc as a leading player in the field of robotic-assisted healthcare navigation.

Stereotaxis Inc is a leading healthcare technology company specializing in robotic surgical systems. Founded in 1990, Stereotaxis has transformed the field of electrophysiology by developing and commercializing innovative robotic platforms. The company's proprietary technology enables physicians to perform precise and minimally invasive procedures, improving patient outcomes. Stereotaxis' versatile robotic systems, including the Niobe® Magnetic Navigation System, have gained recognition for their exceptional precision and safety. With a strong commitment to technological advancements, Stereotaxis Inc continues to revolutionize the medical industry, providing healthcare professionals with cutting-edge tools for improved patient care.

The main competitors of Stereotaxis Inc in the market include XYZ Corporation, ABC Corporation, and LMN Corporation.

Stereotaxis Inc is primarily active in the healthcare industry.

Stereotaxis Inc is a leading company in the field of medical technology. The business model of Stereotaxis Inc revolves around providing innovative robotic systems for use in hospitals and medical facilities. These systems assist healthcare professionals in performing minimally invasive procedures, especially in the field of electrophysiology. By combining advanced robotics and precise imaging, Stereotaxis Inc enables physicians to navigate catheters and devices with enhanced accuracy and control. This ultimately improves patient outcomes and reduces the risks associated with traditional surgical methods. With a focus on medical innovation, Stereotaxis Inc continues to revolutionize the healthcare industry through its state-of-the-art robotic technologies.

Stereotaxis의 P/E 비율은 -7.9입니다.

Stereotaxis의 P/S 비율은 6.17입니다.

Stereotaxis에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Stereotaxis 매출은 27.08 백만 USD입니다.

예상되는 Stereotaxis 이익은 -21.16 백만 USD입니다.

The company Stereotaxis Inc has developed an innovative business model that revolutionizes the diagnosis and treatment of heart diseases. The company is a leader in the development of technologies for magnetic catheter treatment, a minimally invasive method for treating heart diseases. Stereotaxis is a global company based in the USA and operates in Europe, Asia, and Australia. The company develops and produces magnetic catheter systems used by cardiologists to treat heart diseases in patients. Stereotaxis' magnetic catheter technology enables precise navigation through the body using an electric magnetic field. The application can be done minimally invasively without surgery. The technology consists of a catheter controlled by a computer. The doctor navigates the catheter using a magnetic field and visualizes the position of the catheter on a screen. Stereotaxis' flagship product is the "Niobe" magnetic catheter system. The system consists of various components, including a computer, a console, a control unit, sensors, catheters, and accessories. The Niobe system has been approved by the US Food and Drug Administration (FDA) and is used by cardiologists worldwide. In addition to selling magnetic catheter systems for the treatment of heart diseases, Stereotaxis also offers services such as the management of magnetic catheter labs. The company provides installation and training services for doctors and medical personnel to ensure effective use of the system. Stereotaxis is not only a hardware provider but also a provider of imaging and diagnostic software. Their "Odyssey" system provides a comprehensive platform for processing patient data and integrating medical devices. Odyssey enables better real-time collaboration among medical personnel and provides opportunities for data analysis. Stereotaxis operates a product focused on data collection and analysis, "Vdrive". Vdrive is a wireless and user-friendly instrument for documenting and recording information during invasive cardiology procedures by medical personnel. It enables the management of patient and procedure data, workflow optimization, and quality management. In addition, Stereotaxis offers a comprehensive fleet of service technicians. Operating globally, it provides 24/7 maintenance and support for the technical equipment in cardiology laboratories. Stereotaxis also has a dedicated marketing department for its customers, which organizes symposia, workshops, and conferences among other activities. Overall, Stereotaxis offers a comprehensive range of products and services for magnetic catheter treatment. With their latest innovations in mixed reality technology and zebra MRI system, the company will continue to conduct groundbreaking research and push the boundaries of medical science.

Stereotaxis은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Stereotaxis의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Stereotaxis의 ISIN은 US85916J4094입니다.

Stereotaxis의 WKN은 A1J09L입니다.

Stereotaxis의 티커는 STXS입니다.

지난 12개월 동안 Stereotaxis은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Stereotaxis은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Stereotaxis의 현재 배당 수익률은 입니다.

Stereotaxis은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Stereotaxis은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Stereotaxis은 '건강' 섹터에 속합니다.

Stereotaxis의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Stereotaxis는 0 USD를 배당금으로 지급했습니다.

Stereotaxis의 배당금은 USD에 지급됩니다.